Influence of Mid-Trimester Amniotic Fluid on Endogenous and Lipopolysaccharide-Mediated Responses of Mononuclear Lymphoid Cells
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
WITKIN, Steven S.
CHERVENAK, Joseph
BONGIOVANNI, Ann Marie
HERWAY, Catherine
SKUPSKI, Daniel
Citação
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, v.67, n.1, p.28-33, 2012
Resumo
Problem We evaluated the influence of amniotic fluid (AF) on immune mediator production by mononuclear leukocytes. Method of study Thirty mid-gestation AFs were incubated with peripheral blood mononuclear cells (PBMCs) in the presence or absence of lipopolysaccharide (LPS). Supernatants were tested for interleukin (IL) -6, 10, 12, 23, tumor necrosis factor-alpha (TNF-alpha) and monocyte chemotactic protein (MCP)-1. Results Endogenous mediator production was minimal or non-detectable. AF stimulated endogenous MCP-1, IL-6 and TNF-alpha release. In the presence of LPS, production of MCP-1 and IL-10 by PBMCs was enhanced eightto ninefold by AF. Release of IL-6 and IL-23 was enhanced less than twofold by the addition of AF while TNF-alpha production was unchanged. AF-stimulated mediator production was similar irrespective of pregnancy outcome. Conclusion Selective AF stimulation of LPS-mediated MCP-1 and IL-10 release may be a mechanism to promote antibody production and the influx of phagocytic cells to engulf pathogens while downregulating the production of pro-inflammatory cytokines.
Palavras-chave
Amniotic fluid, cytokines, immune regulation, lipopolysaccharide
Referências
- Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
- Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea
- Baggia S, 1996, J SOC GYNECOL INVEST, V3, P121, DOI 10.1016/1071-5576(96)00002-0
- Chaiworapongsa T, 2002, J Matern Fetal Neonatal Med, V12, P159, DOI 10.1080/713605644
- Chow SSW, 2008, CYTOKINE, V44, P78, DOI 10.1016/j.cyto.2008.06.009
- Denison FC, 1998, HUM REPROD, V13, P2292, DOI 10.1093/humrep/13.8.2292
- Esplin MS, 2005, J MATERN-FETAL NEO M, V17, P365, DOI 10.1080/14767050500141329
- Esplin MS, 2005, PLACENTA, V26, P661, DOI 10.1016/j.placenta.2004.09.012
- Gomez-Lopez N, 2010, J LEUKOCYTE BIOL, V88, P625, DOI 10.1189/jlb.1209796
- Jacobsson B, 2003, AM J OBSTET GYNECOL, V189, P1161, DOI 10.1067/S0002-9378(03)00594-5
- Jean-Pierre C, 2006, AM J OBSTET GYNECOL, V194, P694, DOI 10.1016/j.ajog.2006.01.066
- Jones SA, 2005, J IMMUNOL, V175, P3463
- Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481
- LANG AK, 1994, CLIN EXP IMMUNOL, V97, P158
- Marconi C, 2011, AM J REPROD IMMUNOL, V65, P549, DOI 10.1111/j.1600-0897.2010.00940.x
- Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
- Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47
- O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
- Pockley AG, 2008, TRENDS BIOCHEM SCI, V33, P71, DOI 10.1016/j.tibs.2007.10.005
- Robertson SA, 2006, J IMMUNOL, V177, P4888
- Sadowsky DW, 2006, AM J OBSTET GYNECOL, V195, P1578, DOI 10.1016/j.ajog.2006.06.072
- Sadowsky DW, 2003, AM J OBSTET GYNECOL, V188, P252, DOI 10.1067/mob.2003.70
- Sezen D, 2009, AM J OBSTET GYNECOL, V200, p191e1
- Sezen D, 2009, J REPROD IMMUNOL, V82, P89, DOI 10.1016/j.jri.2009.05.004
- SHOHAT B, 1988, INT J FERTIL, V33, P273
- Steer P, 2005, BJOG-INT J OBSTET GY, V112, P1, DOI 10.1111/j.1471-0528.2005.00575.x
- Witkin SS, 2011, BJOG, V118, P144
- Xing LY, 2003, SHOCK, V20, P10, DOI 10.1097/01.shk.0000065704.84144.a4
- Yoon BH, 1996, OBSTET GYNECOL, V87, P231, DOI 10.1016/0029-7844(95)00380-0
- Yost NP, 2000, CLIN OBSTET GYNECOL, V43, P759, DOI 10.1097/00003081-200012000-00006